Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vericel (VCEL) reports robust Q4 earnings and eyes market expansion

Vericel (VCEL) closed 2022 with strong financial and business results, setting the stage for continued growth and profitability in 2023.
The company's focus on innovation, market expansion, and financial discipline underscores its commitment to long-term success.
Despite challenges in regulatory approvals and operational timelines, Vericel (VCEL) remains optimistic about its growth prospects and market positioning.

Vericel reports robust Q1 earnings, raises revenue guidance significantly

Vericel's Q1 performance reflects resilience and growth, with a focus on expanding revenue streams and market presence through product development and commercialization efforts.
While facing challenges in managing expenses and achieving profitability, the company's strong financial position and revenue guidance revisions signal confidence in its growth trajectory.
By capitalizing on MACI's success, navigating upcoming product launches, and maintaining financial discipline, Vericel is poised for continued success and market expansion in the regenerative medicine space.

Vericel reports robust Q2 earnings, eyes growth through new products

Vericel's strong Q2 performance and raised revenue guidance indicate a positive outlook for the company.
Challenges with NexoBrid distribution and MACI conversion rates require focused strategies for growth.
Opportunities lie in upcoming product launches and targeted sales approaches to drive revenue growth.

Vericel reports record Q3 revenue, raises guidance for 2023

Vericel's Q3 performance was exceptional, setting the stage for continued growth.
The company's strong financial position and product strategies bode well for future success.
Anticipated revenue growth in 2024 and expansion plans signal positive momentum.
Vericel aims for a robust finish in 2023 and sustained growth in 2024.

Vericel (VCEL) posts record Q4 revenue, eyes sustained growth

Vericel (VCEL) delivered robust financial results in Q4 2023, with strong revenue growth, operational efficiency, and positive market feedback on key products.
The company is well-positioned for future growth with new product launches, improved margins, and resolved customer dynamics enhancing market stability.
While challenges exist in maintaining growth momentum and managing quarterly margins, strategic investments and market opportunities offer avenues for sustained success.

Vericel (VCEL) posts stellar Q1 results, eyes market expansion

Vericel delivered a robust performance in Q1 2024, marked by revenue growth, profitability surge, and raised full-year guidance.
The company's strengths lie in margin expansion efforts, strategic investments, and plans for market expansion through new initiatives and surgeon targeting.
Challenges include balancing expenses with profitability targets and ensuring rapid adoption of new products among diverse surgeon segments.
Opportunities abound in operational efficiencies, market expansion strategies, and potential for accelerated growth based on product advantages and market positioning.

Vericel reports record Q2 revenue, eyes growth through new launches

Vericel delivered a strong performance in Q2 2024 with record revenue and profitability, driven by MACI and operational efficiency.
While facing challenges with Epicel revenue variability, the company remains optimistic about growth opportunities and market expansion.
With a focus on product launches, FDA approvals, and financial strength, Vericel is well-positioned for continued growth and success in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12, 2023.

Vericel to Present at the Morgan Stanley Global Healthcare Conference

Vericel Corporation (VCEL) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago.

Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates

Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year MACI Revenue Growth of 27% to $36.3 Million Epicel Revenue Growth of 17% to $9.6 Million Full-Year 2023 Revenue Guidance Raised to $190-197 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2023, and provided updated full-year 2023 financial guidance.

Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023

Vericel Corporation demonstrates consistent growth in its core product lines, including MACI for cartilage repair and Epicel for severe burn treatment, with significant competitive advantages and barriers to entry. The company is expanding its market share and exploring new applications for its products, such as MACI for ankle defects, which could increase its total addressable market by $1 billion. Despite some risks, including limited direct competition and potential growth limits, Vericel is well-positioned financially and expected to achieve net profitability within the next 12-18 months.

Vericel: Multiyear Growth Catalysts, Proprietary Solutions Will Drive Market Cap Expansion

Vericel Corporation (NASDAQ:VCEL ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Eric Burns - Vice President, Finance and Investor Relations Nick Colangelo - President and CEO Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Sam Brodovsky - Truist Securities Jeffrey Cohen - Ladenburg Thalmann George Sellers - Stephens Sean Lee - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.

Vericel Corporation (VCEL) Q1 2023 Earnings Call Transcript

Vericel Corporation (VCEL) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.15 per share a year ago.

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Record First Quarter Total Revenue of $41 Million MACI Revenue Increased 32% to $34.2 Million Full-Year 2023 Revenue Guidance Raised to $184-$192 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2023, and provided updated full-year 2023 financial guidance.

Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Sigilon Therapeutics

CHICAGO , May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D.

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D.

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023

The FDA's recent approval of NexoBrid for the treatment of burns is expected to drive revenue growth in 2023. Vericel's MACI autologous cell therapy product for knee cartilage defects is on track for a potential accelerated commercial launch in 2024.

Vericel Corporation: A Promising Future In Advanced Cell Therapies

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 12:30 p.m. ET (9:30 a.m. PT) on Tuesday, March 7, 2023.

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023

Vericel Corporation (NASDAQ:VCEL ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eric Burns – Head-Financial Planning and Analysis and Investor Relations. Nick Colangelo – President and Chief Executive Officer Joe Mara – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG Sam Brodovsky – Truist Securities Jeffrey Cohen – Ladenburg Sean Lee – HC Wainwright Operator Ladies and gentlemen, thank you for standing by.

Vericel Corporation (VCEL) Q4 2022 Earnings Call Transcript

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates

Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth

Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 financial results on Thursday, February 23, 2023. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.

Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

Full-Year Total Revenue Expected to be Approximately $164 to $165 Million

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia.

Kytopen Appoints Paul K. Wotton, Ph.D.

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to begin at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 11, 2023.

Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

Various ongoing fundamental improvements signal significant upsides. The recent NexoBrid approval foretells leaping sales growth in the coming quarters.

Vericel: Aggressive Growth In 2023

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

Vericel Corporation (NASDAQ:VCEL ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Sam Brodovsky - Truist Securities Jeffrey Cohen - Ladenburg Thalmann George Sellers - Stephens Operator Ladies and gentlemen, thank you for standing by. Welcome to the Vericel's Third Quarter 2022 Conference Call.

News for Vericel Stock (VCEL)